Clinical Trial Update: Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating KAI-1678 for pain in postherpetic neuralgia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• KAI-1678

Snippet

Sponsor: KAI Pharmaceuticals | Conditions: Postherpetic Neuralgia | Phase 2 | Status: COMPLETED